View Cart  

Japan: PMDA Notice Shows Increasing Willingness to Accept Global Clinical Trials

A A
Japan’s Pharmaceutical and Medical Devices Agency (PMDA) cited increasing regulatory cooperation with China and South Korea in saying it will now accept new drug applications that rely on well-designed, well-conducted global clinical trials in the neighboring East Asian nations. Includes the full text of Japan’s Basic Principles on Foreign Clinical Trials.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00